Viewing nowPregabalin Capsule 50 mg (Pregabalin)
Pregabalin 50mg
Hard capsule · Prescription medication
Korea Pharmaceutical Co., Ltd.

MFDS item code 201802138 · Approved 2018.05.21 · Insurance code 642803090
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to relieve peripheral and central neuropathic pain in adults and is also utilized as an adjunct for treating partial seizures in epilepsy patients. It is effective in alleviating pain associated with fibromyalgia. This medication assists in improving various neurological disorders and pain symptoms.
This drug is administered orally, regardless of food, in 2 divided doses per day, with the total daily dose expressed as pregabalin. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This drug may be administered at an initial dose of 150mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300mg per day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600mg per day. 2) Central Neuropathic Pain Adults: This drug may be administered at an initial dose of 150mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300mg per day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300mg∼450mg per day. The initial dose is 75mg twice daily (150mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg per day). For patients who do not experience sufficient benefit at a dose of 300mg per day, the dose may be increased within 1 week to 225mg twice daily (450mg per day). Clinical studies have also been conducted at a dose of 600mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg per day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys unchanged. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This drug is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours) In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25 (mg/day), maximum dose 100 (mg/day), single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the dosing regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended in children under 12 years of age or adolescents aged 12∼17 years because sufficient safety and efficacy data are not available.
This medication may increase the risk of suicidal thoughts or behaviors, so if there are any changes in mood or behavior during use, it is important to inform healthcare professionals. Patients with hypersensitivity to this medication or certain genetic issues like lactose intolerance should not use it. Diabetes patients should be cautious as they may need dosage adjustment for blood sugar management due to weight gain. If allergic reactions such as angioedema occur, the medication should be discontinued immediately and healthcare professionals should be consulted. Elderly patients may be at risk of falls due to dizziness or drowsiness, so extra caution is needed, especially at the beginning of treatment. Temporary blurring of vision or changes in sight may occur, but symptoms may improve upon discontinuation of the medication. Abrupt discontinuation of this medication may cause withdrawal symptoms such as insomnia, headaches, and anxiety; therefore, it should be reduced gradually according to healthcare professionals' instructions. Patients with a history of substance abuse should be cautious with this medication due to the increased risk of abuse. Patients with impaired kidney function may require dosage adjustment. Patients with cardiovascular disease should use this medication cautiously based on a physician's judgment. Care should be taken when using with opioid analgesics due to the risk of central nervous system depression. Patients with respiratory or neurological diseases, as well as the elderly, should consult with healthcare professionals before use due to the risk of severe respiratory depression. Women of childbearing age should use effective contraception due to the risk of fetal malformation if used in early pregnancy and should only take it during pregnancy under special circumstances. It is important to check if this medication causes drowsiness or dizziness before driving or operating dangerous machinery. Severe skin adverse reactions may occur, so if any skin abnormalities arise, the medication should be discontinued immediately and healthcare professionals should be notified. This medication has fewer interactions with other drugs; however, side effects may increase when used with central nervous system depressants, so caution is advised. There is limited data on its use during pregnancy, and during breastfeeding, it is recommended to discontinue either breastfeeding or the medication, as it is passed into breast milk. Elderly patients may experience slower excretion of this medication due to decreased kidney function, which may necessitate dosage adjustments. Overdose may lead to symptoms such as confusion, drowsiness, and depression, and hemodialysis or other treatments may be required if necessary. Keep out of reach of children, and transferring medication to another container may pose risks of accidents and quality degradation.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering, and it is best to keep it at room temperature between 15 and 30 degrees Celsius. By storing it this way, the effectiveness of the medication can be maintained, and deterioration can be prevented.
A hard capsule with a dark blue upper part and a white lower part containing a white powder that is white or pale yellow.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Hard capsule · Prescription medication
Korea Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.